RxDoctor Payments Data

Tracy Ann Williams, DO

Internal Medicine · Peekskill, NYNPI 1093964843

Payments from drug & device makers

$984in general payments, 2019–2025

Across 49 payments — averaging $20.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$159
  • Boehringer Ingelheim$122
  • Pfizer$107
  • Novo Nordisk$107
  • GSK$81
  • Bayer$68
  • plus $341 from 9 others

What the payments were for

  • Food & beverage$96598%
  • Education$202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$984 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$84,498
Medicare patients
223
Services billed
909

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$56,563
EliquisApixaban26$38,568
MounjaroTirzepatide22$32,949
RybelsusSemaglutide19$26,557
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$20,282
Breo ElliptaFluticasone/Vilanterol11$7,030
Combivent RespimatIpratropium/Albuterol Sulfate11$6,139
Buprenorphine13$4,780
SymbicortBudesonide/Formoterol Fumarate14$3,247
Albuterol Sulfate HfaAlbuterol Sulfate112$2,783
Rosuvastatin Calcium111$2,002
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$1,720
SynthroidLevothyroxine Sodium17$1,713
Levothyroxine Sodium120$1,559
Atorvastatin Calcium156$1,416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$107$83,12149 claims
PfizerEliquis$107$38,56826 claims
Lilly USA, LLCMounjaro$159$32,94922 claims
GSKTrelegy Ellipta, Breo Ellipta$81$27,31239 claims
Boehringer IngelheimCombivent Respimat$122$6,13911 claims
AstraZenecaSymbicort$65$3,24714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Peekskill

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →